Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Drug-coated Balloons short
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Citation:
European Cardiology Review 2018;13(1):9–13.
- Views:
311
- Downloads:
0
Familial Hypercholesterolaemia Diagnosis and Management
Citation:
European Cardiology Review 2018;13(1):14–20.
- Views:
677
- Downloads:
0
Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Citation:
European Cardiology Review 2018;13(1):38–41.
- Views:
274
- Downloads:
0
Novel Pharmacologic Treatments for Cardiovascular Disease: A Practical Update
Citation:
US Cardiology Review 2017;11(2):98–104.
- Views:
1276
- Downloads:
0